Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALB | P02768 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | TK1 | P04183 | 6/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6314490 | 1.00 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL7701755 | 1.00 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL1130181 | 1.00 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL6760136 | 1.00 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL1129572 | 1.00 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14580339 | 0.87 | TK1 (0.48) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL2920441 | 0.86 | TK1 (0.52) | LMNATK1 | |
| SCHEMBL2920443 | 0.86 | TK1 (0.52) | LMNATK1 | |
| SCHEMBL6753208 | 0.84 | SMN1; SMN2 (0.54) | LMNABLMALDH1A1POLBADRA1A | |
| SCHEMBL6752642 | 0.84 | LMNA (0.60) | LMNAADRA1ATK1TSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| CN-114901657-A | Antiviral and liver-targeting drugs | 人工智能生物制药公司 | 2022-08-12 | — | — | CN | claimed |
| EP-1693373-A1 | Enantiomerically pure beta-D-(-)-dioxolane-nucleosides | EMORY UNIVERSITY (US) | 2006-08-23 | — | — | EP | claimed |
| EP-1600448-A2 | Enantiomerically pure beta-D-(-)-Dioxolane-Nucleosides | University of Georgia Research Foundation, Inc. (US) | 2005-11-30 | — | — | EP | claimed |
| EP-0562009-A4 | ENANTIOMERICALLY PURE -G(B)-D-(-)-DIOXOLANE-NUCLEOSIDES | — | 1993-11-24 | — | — | EP | claimed |
| EP-0562009-A1 | ENANTIOMERICALLY PURE $g(b)-D-(-)-DIOXOLANE-NUCLEOSIDES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1993-09-29 | — | — | EP | claimed |
| US-5179104-A | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1993-01-12 | — | — | US | claimed |
| WO-1992010497-A1 | ENANTIOMERICALLY PURE β-D-(-)-DIOXOLANE-NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-06-25 | — | — | WO | claimed |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | A-BIOPHARMA (FR) | 2026-02-03 | — | — | US | disclosed |
| EP-4611757-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | Ramirez, Christina, M. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| US-5248776-A | Multistage reaction with sulfiding, cyclization and oxidative cleavage | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1993-09-28 | — | — | US | disclosed |
| US-5179104-A | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1993-01-12 | — | — | US | disclosed |
| WO-1992014729-A1 | ANTIVIRAL 1,3-DIOXOLANE NUCLEOSIDES AND SYNTHESIS THEREOF | EMORY UNIVERSITY (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992010496-A1 | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010497-A1 | ENANTIOMERICALLY PURE β-D-(-)-DIOXOLANE-NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | HAVCR2, NR1H4, NR1H3 | LMNA 1280/4885ALB 3076/4885BLM 4047/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | LMNA 1661/4885ALB 3481/4885BLM 4147/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | LMNA 4334/4885ALB 3655/4885BLM 4565/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | LMNA 2736/4885ALB 315/4885BLM 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.